

BOLETIM RAMB COVID-19

Número 7
3 de maio de 2020

COVID-19: the virus in the control of culture?

*Lincoln Lopes Ferreira
Antonio Carlos P. Chagas
Wanderley M. Bernardo*

Em um momento em que há uma emergência mundial de saúde pública, é fundamental que o conhecimento científico gerado durante a pandemia chegue rapidamente à classe médica classe médica.

Dentro desta dinâmica a Revista da Associação Médica Brasileira (Ramb) está adotando uma série de medidas a fim de acelerar o processo editorial para publicação de artigos sobre a Covid-19. A partir de hoje (14/04/2020), a AMB publicará o Boletim Ramb Covid-19, que antecipará os artigos científicos selecionados pelos editores da Ramb sobre o tema.

“Os artigos foram escritos por especialistas e selecionados dentro dos critérios da Ramb para esclarecer temas fisiopatológicos, assim como oferecer orientações de prevenção e tratamento da doença. Dessa forma, esperamos colaborar com os médicos para o melhor atendimento aos seus pacientes, com a disponibilidade mais ágil desses artigos, antes de sua publicação na Ramb”, comenta Carlos Serrano Jr., editor-chefe da Ramb.

Para o diretor científico da AMB, Antonio Carlos Palandri Chagas, “neste momento ímpar vivido no mundo por conta da pandemia de Covid-19, a AMB cumpre seu papel de estar levando à comunidade científica brasileira os recentes artigos sobre os mecanismos fisiopatológicos e aspectos clínicos relevantes dessa situação que assola a saúde pública”.



Carlos Serrano Jr.



Antonio Carlos Palandri Chagas

EDITORIAL BOARD

EDITORS-IN-CHIEF

Carlos V. Serrano Jr.
José Maria Soares Jr.

CO-EDITOR

Wanderley M. Bernardo

MANAGING EDITOR

César Teixeira

ASSOCIATED EDITORS

Albert Bousso
Sérgio C. Nahas

SPECIALTY EDITORS

ACUPUNCTURE

Ari Ojeda Ocampo Moré
Pedro Cavalcante
Dirceu de Lavôr Sales
Marcia Lika Yamamura
Hildebrando Sábato
Fernando Claudio Genschow

ALLERGY AND IMMUNOLOGY

Herberto José Chong Neto
Luis Felipe Chiaverini Ensina
Pedro Francisco Giavina-Bianchi Júnior

ANAESTHESIOLOGY

Marcos Antonio Costa de Albuquerque
Maria Angela Tardelli
Maria José Carvalho Carmona
Rogean Rodrigues Nunes

ANGIOLOGY AND VASCULAR SURGERY

Marcelo Fernando Matielo
José Fernando Macedo
José Aderval Aragão
Arno Von Ristow
Daniel Mendes Pinto

CARDIOLOGY

Wolney de Andrade Martins
Olimpio Ribeiro França Neto
Otavio Rizzi Coelho Filho
Pedro Silvio Farsky
Humberto Graner Moreira

CARDIOVASCULAR

Eduardo Augusto Victor Rocha
João Carlos Ferreira Leal
Rui M. S. Almeida

CLINICAL PATHOLOGY / LABORATORY MEDICINE

Álvaro Pulchinelli Júnior
Maria Elizabete Mendes
Marinês Dalla Valle Martino
Silvana Maria Elói Santos

COLOPROCTOLOGY

Fábio G. Campos
Sergio Nahas

DERMATOLOGY

Mauro Yoshiaki Enokihara
Flávia Bittencourt

DIGESTIVE ENDOSCOPY

Adriana Safatle

DIGESTIVE SURGERY

Bruno Zilberstein
Nelson Andreollo
Oswaldo Malafaia
Carlos Eduardo Jacob

EMERGENCY MEDICINE

Hélio Penna Guimarães
Marcus Vinícius de Andrade
Júlio Marchini

ENDOCRINOLOGY AND METABOLISM

Márcio Corréa Mancini
Manoel Ricardo Alves Martins

Auro Del Giglio

Claudia Leite

Edna Frasson de S. Montero

Eduardo F. Borba

Elias Jirjoss Ilias

Isabela Giuliano

Lucia Pellanda

Paulo Kassab

Werther B. W. de Carvalho

Linamara Batistella

Dimas Ikeoki

Anna Andrei

Maria Laura Costa do Nascimento

FAMILY AND COMMUNITY MEDICINE

Thiago Sarti
Leonardo Fontenelle

GASTROENTEROLOGY

João Galizzi Filho
André Castro Lyra
Raquel Canzi Almada de Souza

GENERAL SURGERY

Luiz Carlos Von Bahten
Pedro Eder Portari Filho
Rodrigo Felipe Ramos

GERIATRICS AND GERONTOLOGY

Vitor Last Pintarelli

GYNAECOLOGY AND OBSTETRICS

César Eduardo Fernandes
Corintio Mariani Neto
Rosiane Mattar
Edmund Chada Baracat

HAND SURGERY

João Baptista Gomes dos Santos
Samuel Ribak
Antonio Carlos da Costa

HEAD AND NECK SURGERY

Antonio Jose Gonçalves
Flávio Carneiro Hojaij
José Guilherme Vartanian
Leandro Luongo Matos

HEMATOLOGY AND HEMOTHERAPY

Fernando Ferreira Costa

HOMEOPATHY

Silvia Irene Waisse Priven

INFECTIOUS DISEASES

Helio Bacha
Alexandre Vargas Schwarzböhd

INTENSIVE CARE MEDICINE

Rosane Sonia Goldwasser
Cintia Magalhães Carvalho Grión
Claudio Piras

INTERNAL MEDICINE

Fernando Sabia Tallo
Abrão José Cury Junior

LEGAL MEDICINE AND MEDICAL EXAMINATIONS

Ivan Dieb Miziara
José Jozafra B. Freite

MASTOLOGY

Gil Facina
Rene Aloisio da Costa Vieira
Ruffo de Freitas Junior

MEDICAL GENETICS

Vera Lucia Gil da Silva Lopes

NEUROSURGERY

Luis Alencar B. Borba
Jean Gonçalves de Oliveira
José Carlos Esteves Veiga

José Marcus Rotta
Eberval Gadelha Figueiredo
Benedicto Oscar Colli

NEPHROLOGY

Andrea Pio de Abreu
Vinicius Daher Alvares Delfino
David Jose de Barros Machado

NEUROLOGY

Carlos Roberto de Mello Rieder
Marcondes Cavalcante França Jr.

NUCLEAR MEDICINE

Juliano Julio Cerci
Cristina Sebastião Matushita
George Barberio C. Filho
Rafael Willain Lopes

NUTROLOGY

Elza Daniel de Mello
Juliana Machado
Durval Ribas Filho

OCCUPATIONAL MEDICINE

Francisco Cortes Fernandes
Rosylane Nascimento das Mercês Rocha
Andrea Franco Amoras Magalhães

ONCOLOGY

Daniela Rosa
Markus Gifoni
Romualdo Barroso

OPHTHALMOLOGY

Keila Monteiro de Carvalho
Eduardo Melani Rocha

ORTHOPAEDICS AND TRAUMATOLOGY

Marco Kawamura Demange
Benno Ejnisman
Daniel Soares Baumfeld
Alex Guedes
Robinson Esteves Santos Pires

OTOLARYNGOLOGY

Marcio Nakanishi
Luciano Rodrigues Neves
Vinicius Ribas de Carvalho Duarte
Fonseca
Edson Ibrahim Mitre

PAEDIATRIC

Emanuel Savio Cavalcanti Sarinho
Debora Carla Chong e Silvia
Simone Brasil de Oliveira Iglesias

PAEDIATRIC SURGERY

Maria do Socorro Mendonça de Campos
Lisieux Eyer de Jesus
José Roberto de Souza Baratella

PATHOLOGY

Fernando Augusto Soares
Kátia Ramos Moreira Leite

PHYSICAL MEDICINE AND REHABILITATION

Silvia Verst
Eduardo Rocha
Luciana Dotta

INTERNATIONAL EDITORS

Frida Leonetti
Geltrude Mingrone
Giuseppe Barbaro
Marcelo Marotti
Walter Ageno
Michael Farkouh

JUNIOR EDITORS

Matheus Belloni Torsani
Hélio Amante Miot
Rubens Zeron
Luiz de Menezes Montenegro
Gustavo K. Matsui

Ligia Cattai
Marcus Yu Bin Pai

PLASTIC SURGERY

Ricardo Frota Boggio
Rodrigo Gouvea Rosique
Fabio Kamamoto

PREVENTIVE MEDICINE AND HEALTH ADMINISTRATION

Antonio Eduardo Fernandes D'Aguilar
Milton Massayuki Osaki
Helio Komagata

PSYCHIATRY

Antônio Geraldo da Silva
Itiro Shirakawa
Francisco Baptista Assumpção Junior
Leonardo Rodrigo Baldaçara
Sérgio Tamai

PULMONOLOGY / PHTHISIOLOGY

José Miguel Chatkin
Marcelo Fouad Rabahi
Rodrigo Luis Barbosa Lima
Rosemeri Maurici da Silva

RADIOTHERAPY

Arthur Accioly Rosa
Gustavo Nader Marta
Gustavo Viani Arruda
Mauricio Fraga da Silva

RADIOLOGY

Alair Sarmet
Valdair Muglia
Dante Luiz Escussato
Luciana Costa Silva
Claudia Leite
Manoel Rocha

RHEUMATOLOGY

Eduardo dos Santos Paiva

SPORTS MEDICINE

André Pedrinelli;
Fernando Carmelo Torres
Marcelo Bichels Leitão.

SURGICAL ONCOLOGY

Alexandre Ferreira Oliveira
Reitan Ribeiro
Gustavo Andreazza Laporte

TRAFFIC MEDICINE

José Heverardo da Costa Montal
Arlison de Souza Carvalho Junior
Egas Caparelli Moniz de Aragão Dáquer

THORACIC SURGERY

Darcy Pinto
Carlos Alberto Araujo
Ricardo Terra

UROLOGY

Eduardo Carvalhal
Gilberto Almeida
Stênio Zequi
Lucas Teixeira A. Batista
Francisco Bretas

**ASSOCIAÇÃO MÉDICA BRASILEIRA (BRAZILIAN MEDICAL ASSOCIATION)
MANAGEMENT BOARD 2017-2020**



PRESIDENT

Lincoln Lopes Ferreira (Minas Gerais)

1ST VICE-PRESIDENT

Diogo Leite Sampaio (Mato Grosso)

2ND VICE-PRESIDENT

Robson Freitas de Moura (Bahia)

VICE-PRESIDENTS

José Luiz Dantas Mestrinho – Mid-West (Federal District)

Arno Buertiner Von Ristow – Southeast (Rio de Janeiro)

Eduardo Francisco de Assis Braga – North (Tocantins)

Mauro Cesar Viana de Oliveira – Northeast (Maranhão)

Alfredo Floro Cantalice Neto – South (Rio Grande do Sul)

GENERAL SECRETARY

Antônio Jorge Salomão (São Paulo)

1ST SECRETARY

Carmita Helena Najjar Abdo (São Paulo)

1ST TREASURER

Miguel Roberto Jorge (São Paulo)

2ND TREASURER

José Luiz Bonamigo Filho (São Paulo)

CULTURAL DIRECTOR

Fernando Antonio Gomes de Andrade (Alagoas)

DIRECTOR OF CORPORATE RELATIONS

Carlos Alfredo Lobo Jasmin (Rio de Janeiro)

DIRECTOR OF INTERNATIONAL RELATIONS

Eduardo Nagib Gaudi (Rio de Janeiro)

SCIENTIFIC DIRECTOR

Antonio Carlos Palandri Chagas (São Paulo)

ACADEMIC DIRECTOR

Maria José Martins Maldonado (Mato Grosso do Sul)

DIRECTOR OF MEMBER SUPPORT SERVICES

Marcio Silva Fortini (Minas Gerais)

DIRECTOR OF PARLIAMENTARY AFFAIRS

Débora Eugenia Braga Nóbrega Cavalcanti (Paraíba)

**RAMB - REVISTA DA ASSOCIAÇÃO MÉDICA BRASILEIRA
(JOURNAL OF THE BRAZILIAN MEDICAL ASSOCIATION)**

RAMB

EDITORS-IN-CHIEF: *Carlos V. Serrano Jr. and José Maria Soares Jr.*

CO-EDITOR: *Wanderley M. Bernardo*

MANAGING EDITOR: *César Teixeira*

E-MAIL: *ramb@amb.org.br*

WEBSITE: *www.ramb.org.br*

Address: Rua São Carlos do Pinhal, 324

Bela Vista – São Paulo

Postal Code: 01333-903

Phone no.: (+55 11) 3178-6800 Ext. 177

The RAMB, Journal of The Brazilian Medical Association, is an official publication of the Associação Médica Brasileira (AMB – Brazilian Medical Association), indexed in Medline, Science Citation Index Expanded, Journal Citation Reports, Index Copernicus, Lilacs, and Qualis B2 Capes databases, and licensed by Creative Commons®. Registered in the 1st Office of Registration of Deeds and Documents of São Paulo under n. 1.083, Book B, n. 2.

Publication norms are available on the website www.ramb.org.br

All rights reserved and protected by Law n. 9.610 – 2/19/1998. No part of this publication may be reproduced without prior written authorization of the AMB, whatever the means employed: electronic, mechanical, photocopying, recording or other.

THE RAMB IS INDEXED IN SCIELO - SCIENTIFIC ELECTRONIC LIBRARY ONLINE.



TIMBRO EDITORA

PUBLISHER: *Rodrigo Aguiar*

AUTHORIZING EDITOR: *Luciano Bauer Grohs*

EDITOR: *Celina Maria Morosino Lopes*

PRODUCER: *Maria Fortes*

EDITORIAL PRODUCER: *Helvânia Ferreira*

ENGLISH TRANSLATION OF ARTICLES: *Alpha & Omega*

REFERENCE REVIEWER: *Rosângela Monteiro*

PROOFREADING: *Hebe Ester Lucas e Alpha & Omega*


GRAPHIC DESIGN: *Angela Mendes e Murilo M. Camargo*




The advertisements and opinions published in the Ramb are the sole responsibility of the advertisers and authors. The AMB and Timbro Comunicação are not responsible for its content.

COVID-19: the virus in the control of culture?

Lincoln Lopes Ferreira¹

 Antonio Carlos P. Chagas²

 Wanderley M. Bernardo³

1. Presidente da Associação Médica Brasileira, São Paulo, SP, Brasil

2. Diretor Científico da Associação Médica Brasileira, São Paulo, SP, Brasil

3. Coordenador do Programa Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brasil

Much has been written and published about COVID-19. There are more than 5,000 works within the past 3 months, varying in themes like etiology, diagnosis, treatment and prognosis, with many more still to be published¹⁻¹⁵.

There are countless estimates and predictions on viral progression, whether related to the doubling rate (e.g. 2.5 times per patient), multiplication factors (e.g. 23), indirect calculations based on mortality (e.g. 1%), or even the association of all these factors, leading to corrections in the number of reported cases in the order of 6, up to 80 times, called by some as optimistic or pessimistic.

The equal adjustment of lethality and mortality rates has occupied the time of many mathematicians, statisticians, epidemiologists and health professionals, in an attempt to contribute to decision making of the system.

There're several discussions about horizontal or vertical lockdowns, social distancing (varying from 1 to 7.5 meters), types of masks for asymptomatic patients (cloth, medical or surgical), masks for sick patients (medical or surgical), and morbidities that increase the risk of severity.

It has been discussed which individual protection materials health professionals should use (e.g., N95 masks), and regarding the hospital care process, which structural changes are necessary, due to the

increased demand in the Intensive Care Unit (ICU) and hospitalization of patients with COVID-19.

We have heard national and global reports on the difficulty of processing diagnostic tests (e.g. RT-PCR) to effectively identify cases, leading to a point where, most emergency services do not investigate patients with mild symptoms of upper respiratory infection, advising them to return if symptoms worsen. Thus, the identification of COVID-19 cases has been done superficially and is limited to symptomatic cases with signs of severity.

Most global health systems have been overloaded with an unmanageable overflow, creating direct impact on mortality, while feeding into a cycle that impedes the possibility of any organized action in order to administer the local epidemic.

In the search for treatment many opted in, dropped out, opted in again, and dropped out once more, within just a few weeks, as part of an endless and exhausting media dance, whose main objective is clearly the search for solutions; but perhaps desperate and often irresponsible, producing more damage than benefit.

To make matters worse, patients with other “non-COVID” diseases have been naturally neglected, allowing their conditions to unjustly aggravate, consequently increasing the systems inefficiency and amount of damage.

These negative experiences are striking, and invariably make us forget about successful initiatives (as such seen in South Korea), holding our attention to an indifferent view: “The same will inevitably happen here”; or perhaps romantic: “Let’s go resist this small microorganism, we are bigger than THAT”.

Up to this point in our reflection, you must be thinking: “I know all of this, and not just me, but everyone knows all of it. What’s the point? What’s the matter in here? Am I reading yet another article that says a lot but makes no recommendations? Is this article an end in itself?”

You are almost right. In fact, our approach here focuses on three (3) slightly more critical aspects and, therefore, may (or may not) be considered in our decision-making strategies:

1. Epidemics are not controlled acutely and exclusively by cultural changes. Those “without knowledge” or perhaps “without appropriate education” should not hold themselves responsible for the consequences, without the opportunity and time to learn in advance. This is like an aggressive agent (in this case, the virus) who blames the victim (patient) for its consequences (death) in themselves (population). To the least, this is an unjust concept – characteristic of an impotent and incompetent system – which should be educating,

protecting and caring for those under one's responsibility;

2. Sick cases (asymptomatic or not) should not be broken down into home "clusters", and here is a natural and non-medical example: this is like dividing the sections in a wildfire into small new sections, which will expand into new fires, and so on. Wildfire is fought with a holistic approach, by locating the focal points, working your way in until the fire sections are extinguished – because you can hide the cases, but you cannot hide the deaths. The inter-cluster transmission is reduced, but the intra-cluster transmission will continue to feed in new cases. The attitude to wait and see what happens without any scientific strategy, is easy, and again transfers the responsibility to the patient in solving the problem;

3. The third aspect relates to the absurd and again unjust attribution of responsibility to "those who must work" and "not just to support" controlling the spread, without minimum working conditions, whether structural or human. Doctors and health-care professionals, generically called the workforce and front-lines, have been neglected, exploited, humiliated, scrapped and devalued in the last 30 years! There's no need for "panels", "clapping" or "homage" to deliver the function they have always fulfilled, regardless of disrespect or lack of adequate resources for their livelihood. Not to mention, these workers when

contaminated or sick, make it difficult to manage their condition, participating involuntarily in the transmission by going to work without testing, diagnosis and care.

Our epidemic companion, the virus, has no conscience, and doesn't even know what it's doing. Its survival is blind and programmed. It ignores all the technology, modern/expensive drugs produced by a selfish and profit-centered industry, who pressures and breaks the health system with ridiculous benefits and assumed damage. Those who are needed most at the moment show their inefficiency to act against a known – over 20 years – "little" agent, which is the cause of so many deaths and suffering.

The "mea culpa" has no use in proposing solutions, but it is fundamental because it establishes memory and responsibilities, alleviating the weight on a population that despite resilient is still vulnerable.

WHAT ARE THE SOLUTIONS?

1. Locate the "little guy" in individuals (at least symptomatic) and their contacts, individually isolating them;

2. Mapping and monitoring cases at the local level, and not at the national level, which is politically and mathematically pointless;

3. Appropriately assisting serious cases so that they feel cared for. Only then, can we attribute outcomes to the "little guy";

4. Investing in the ethical generation of centralized and multicentric scientific evidence, by restraining repeated and self-centered disaggregated efforts;

5. Taking advantage of the opportunity to educate the population, in an understanding and kind manner – at the same time rigorous and adamant – through the reinforcement of democratic thinking, where not everything is allowed when considering others;

6. Seeking equity in a fragmented and inequitable health system, using as a model the private assistance system;

7. Finally, although we know that we're not in control of life, remember that everyone has a role in this process, including the virus. The latter, however, cannot be in control, and its high time that those with responsibility showed that they are the ones in control.

Times passing by, and together the consequences may be – or already are – greater or lesser depending on future decisions.

It is critical to stop investing in a denial strategy, (which only aspires pity from those who know science), and prompt despair in those who don't. ■

Submitted Date: 22/4/2020
Accepted Date: 22/4/2020

REFERENCES

1. Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, et al. Association of Public Health Interventions with the Epidemiology of the COVID-19 Outbreak in Wuhan, China. *JAMA* 2020 Apr 10. doi: 10.1001/jama.2020.6130. PMID: 32275295.
2. Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. *JAMA* 2020. doi: 10.1001/jama.2020.3151. PMID: 32125371.
3. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA*. 2020. doi: 10.1001/jama.2020.4683. PMID: 32203977.
4. Yen MY, Schwartz J, Chen SY, King CC, Yang GY, Hsueh PR. Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: Implications for global prevention and control efforts. *J Microbiol Immunol Infect* 2020. doi: 10.1016/j.jmii.2020.03.011. PMID: 32205090.
5. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. *N Engl J Med* 2020. doi: 10.1056/NEJMs2005114. PMID: 32202722.
6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020. doi: 10.1001/jama.2020.2648. PMID: 32091533.
7. Ioannidis JPA. Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures. *Eur J Clin Invest*. 2020; 50: e13222. doi: 10.1111/eci.13222. PMID: 32191341.

8. Boccia S, Ricciardi W, Ioannidis JPA. What Other Countries Can Learn From Italy During the COVID-19 Pandemic. *JAMA Intern Med* 2020. doi: 10.1001/jamainternmed.2020.1447. PMID: 32259190.
9. Desjardins MR, Hohl A, Delmelle EM. Rapid surveillance of COVID-19 in the United States using a prospective space-time scan statistic: Detecting and evaluating emerging clusters. *Appl Geogr* 2020; 118: 102202. doi: 10.1016/j.apgeog.2020.102202. PMID: 32287518; PubMed.
10. Kim YJ, Jeong YJ, Kim SH, Kim YJ, Lee SY, Kim TY, et al. Preparedness for COVID-19 infection prevention in Korea: Single-center experience. *J Hosp Infect* 2020. pii: S0195-6701(20)30193-6. doi: 10.1016/j.jhin.2020.04.018. PMID: 32302723.
11. Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. *Int J Infect Dis.* 2020; 93: 339-344. doi: 10.1016/j.ijid.2020.03.031. PMID: 32198088.
12. COVID-19 National Emergency Response Center, Epidemiology & Case Management Team, Korea Centers for Disease Control & Prevention. Contact Transmission of COVID-19 in South Korea: Novel Investigation Techniques for Tracing Contacts. *Osong Public Health Res Perspect* 2020; 11:60-63. doi: 10.24171/j.phrp.2020.11.1.09. PMID: 32149043.
13. Diretrizes AMB COVID-19. Disponível em URL: <https://amb.org.br/wp-content/uploads/2020/04/DIRETRIZES-AMB-COVID-19-atualizado-em-09.04.2020.pdf>.
14. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020; 395: 514-523. doi: 10.1016/S0140-6736(20)30154-9. PMID: 31986261.
15. The Lancet. COVID-19 in the USA: a question of time. *Lancet* 2020; 395: 1229. doi: 10.1016/S0140-6736(20)30863-1. PMID: 32305080.